Idorsia (IDIA) Q4 2025 earnings summary

Executive summary

• 2025 marked a year of stabilization, operational recovery, and pivotal restructuring, with QUVIVIQ and TRYVIO/JERAYGO entering value-acceleration phases and a pipeline advancing in immunology and rare diseases.

• QUVIVIQ sales more than doubled year-over-year, driven by strong demand in Europe and Canada, while TRYVIO/JERAYGO gained regulatory approvals in multiple regions and is positioned as a differentiated therapy for resistant hypertension.

• The pipeline advanced with progress in immunology and rare disease programs, including clear regulatory paths and pivotal studies planned for lucerastat in Fabry disease and daridorexant in pediatric insomnia.

• Operational restructuring, debt sequestering, and new financing from equity and debt investors significantly improved the bottom line and reduced net loss.

Financial highlights

• Net revenue for 2025 reached CHF 221 million, with QUVIVIQ product sales at CHF 134 million, up from CHF 61 million in 2024.

• Non-GAAP operating loss improved to CHF 100 million from CHF 308 million in 2024; US GAAP EBIT loss was CHF 33 million, and net loss was CHF 112 million, including CHF 72 million in financial expenses.

• Operating expenses decreased significantly, with US GAAP operating expenses at CHF 268 million and non-GAAP at CHF 328 million.

• Liquidity at year-end was CHF 89 million, excluding CHF 80 million available under a new term loan facility, totaling CHF 169 million available liquidity.

• Revenue for 2025 exceeded guidance of CHF 205 million.

Outlook and guidance

• 2026 guidance projects QUVIVIQ sales of CHF 200 million, with operating expenses expected at approximately CHF 330 million and a forecasted non-GAAP operating loss of CHF 120 million.

• Guidance excludes TRYVIO/JERAYGO revenues and investments, pending partnership agreements.

• Guidance is limited to a one-year horizon due to multiple upcoming inflection points and uncertainties.